An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

Trial Profile

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Sirolimus (Primary) ; Steroids
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top